POST-TEST

Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Patients on the TAILORx trial with ER-positive, HER2-negative, axillary node-negative breast cancer and a Recurrence Score® (RS) of 11 to 25 experienced which of the following with chemoendocrine therapy compared to endocrine therapy alone?**
   a. Marginal benefit with the addition of chemotherapy to endocrine therapy
   b. No benefit with the addition of chemotherapy to endocrine therapy
   c. Significant benefit with the addition of chemotherapy to endocrine therapy

2. **Women aged 50 or younger with ER-positive, HER2-negative, axillary node-negative breast cancer and a RS of 16 to 25 in the TAILORx trial obtained which of the following from chemotherapy?**
   a. No benefit
   b. Some benefit

3. **The SOLAR-1 trial comparing the PI3K inhibitor alpelisib with fulvestrant to fulvestrant alone demonstrated a significant improvement of approximately 5 months in progression-free survival with alpelisib for patients with HR-positive, HER2-negative advanced breast cancer with which PIK3CA mutation status?**
   a. Only patients with a PIK3CA mutation
   b. Only patients without a PIK3CA mutation
   c. Patients with and without a PIK3CA mutation

4. **A meta-analysis conducted by the FDA analyzing clinical benefit for subgroups of patients with ER-positive metastatic breast cancer who received CDK4/6 inhibitors as first- or second-line therapy demonstrated a lack of benefit with this class of agents in which of the following patient subgroups?**
   a. Only patients with de novo metastatic disease
   b. Only patients with lobular carcinoma
   c. Only patients with bone-predominant metastasis
   d. None of the above — a benefit was reported across all subgroups

5. **Which of the following categories best characterizes the mechanism of action of the novel agent capivasertib?**
   a. AKT inhibitor
   b. Aromatase inhibitor
   c. Bcl-2 inhibitor
   d. CDK4/6 inhibitor